1716 related articles for article (PubMed ID: 26614965)
1. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
[TBL] [Abstract][Full Text] [Related]
2. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.
Buchbinder SP; Glidden DV; Liu AY; McMahan V; Guanira JV; Mayer KH; Goicochea P; Grant RM
Lancet Infect Dis; 2014 Jun; 14(6):468-75. PubMed ID: 24613084
[TBL] [Abstract][Full Text] [Related]
3. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
[TBL] [Abstract][Full Text] [Related]
5. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B;
AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
[TBL] [Abstract][Full Text] [Related]
6. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
7. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.
Gandhi M; Glidden DV; Mayer K; Schechter M; Buchbinder S; Grinsztejn B; Hosek S; Casapia M; Guanira J; Bekker LG; Louie A; Horng H; Benet LZ; Liu A; Grant RM
Lancet HIV; 2016 Nov; 3(11):e521-e528. PubMed ID: 27658870
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Landovitz RJ; Hanscom BS; Clement ME; Tran HV; Kallas EG; Magnus M; Sued O; Sanchez J; Scott H; Eron JJ; Del Rio C; Fields SD; Marzinke MA; Eshleman SH; Donnell D; Spinelli MA; Kofron RM; Berman R; Piwowar-Manning EM; Richardson PA; Sullivan PA; Lucas JP; Anderson PL; Hendrix CW; Adeyeye A; Rooney JF; Rinehart AR; Cohen MS; McCauley M; Grinsztejn B;
Lancet HIV; 2023 Dec; 10(12):e767-e778. PubMed ID: 37952550
[TBL] [Abstract][Full Text] [Related]
9. Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): a prospective, single-arm, open-label, multicentre implementation study.
Veloso VG; Cáceres CF; Hoagland B; Moreira RI; Vega-Ramírez H; Konda KA; Leite IC; Bautista-Arredondo S; Vinícius de Lacerda M; Valdez Madruga J; Farias A; Lima JN; Zonta R; Lauria L; Tamayo CVO; Flores HJS; Santa Cruz YMC; Aguayo RMM; Cunha M; Moreira J; Makkeda AR; Díaz S; Guanira JV; Vermandere H; Benedetti M; Ingold HL; Pimenta MC; Torres TS; Grinsztejn B;
Lancet HIV; 2023 Feb; 10(2):e84-e96. PubMed ID: 36565708
[TBL] [Abstract][Full Text] [Related]
10. Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.
Ojeda VD; Amico KR; Hughes JP; Wilson E; Li M; Holtz TH; Chitwarakorn A; Grant RM; Dye BJ; Bekker LG; Mannheimer S; Marzinke M; Hendrix CW
J Acquir Immune Defic Syndr; 2019 Sep; 82(1):34-40. PubMed ID: 31169769
[TBL] [Abstract][Full Text] [Related]
11. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
[TBL] [Abstract][Full Text] [Related]
12. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD
PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059
[TBL] [Abstract][Full Text] [Related]
13. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
Liu AY; Cohen SE; Vittinghoff E; Anderson PL; Doblecki-Lewis S; Bacon O; Chege W; Postle BS; Matheson T; Amico KR; Liegler T; Rawlings MK; Trainor N; Blue RW; Estrada Y; Coleman ME; Cardenas G; Feaster DJ; Grant R; Philip SS; Elion R; Buchbinder S; Kolber MA
JAMA Intern Med; 2016 Jan; 176(1):75-84. PubMed ID: 26571482
[TBL] [Abstract][Full Text] [Related]
14. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
Hoagland B; Moreira RI; De Boni RB; Kallas EG; Madruga JV; Vasconcelos R; Goulart S; Torres TS; Marins LMS; Anderson PL; Luz PM; Costa Leite ID; Liu AY; Veloso VG; Grinsztejn B;
J Int AIDS Soc; 2017 Apr; 20(1):21472. PubMed ID: 28418232
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
[TBL] [Abstract][Full Text] [Related]
16. Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities.
Mimiaga MJ; Closson EF; Battle S; Herbst JH; Denson D; Pitts N; Holman J; Landers S; Mansergh G
AIDS Patient Care STDS; 2016 Oct; 30(10):484-489. PubMed ID: 27749110
[TBL] [Abstract][Full Text] [Related]
17. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
Psaros C; Goodman GR; Lee JS; Rice W; Kelley CF; Oyedele T; Coelho LE; Phanuphak N; Singh Y; Middelkoop K; Griffith S; McCauley M; Rooney J; Rinehart AR; Clark J; Go V; Sugarman J; Fields SD; Adeyeye A; Grinsztejn B; Landovitz RJ; Safren SA;
J Int AIDS Soc; 2024 May; 27(5):e26252. PubMed ID: 38783534
[TBL] [Abstract][Full Text] [Related]
18. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
Songtaweesin WN; Kawichai S; Phanuphak N; Cressey TR; Wongharn P; Saisaengjan C; Chinbunchorn T; Janyam S; Linjongrat D; Puthanakit T;
J Int AIDS Soc; 2020 Sep; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
[TBL] [Abstract][Full Text] [Related]
19. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
[TBL] [Abstract][Full Text] [Related]
20. Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW).
Defechereux PA; Mehrotra M; Liu AY; McMahan VM; Glidden DV; Mayer KH; Vargas L; Amico KR; Chodacki P; Fernandez T; Avelino-Silva VI; Burns D; Grant RM;
AIDS Behav; 2016 Jul; 20(7):1478-88. PubMed ID: 26078115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]